NCT00614042View on ClinicalTrials.gov

Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2012

Conditions
Chronic Lymphocytic Leukemia (CLL)Non-Hodgkin's Lymphoma (NHL)
Interventions
DRUG

TRU-016 (anti-CD37 protein therapeutic)

TRU-016 administered via IV infusion weekly for 8 weeks and then monthly

Trial Locations (7)

27710

For additional information regarding sites for this trial call 919-319-9374, Durham

30912

For additional information regarding sites for this trial call 919-319-9374, Augusta

35294

For additional information regarding sites for this trial call 919-319-9374, Birmingham

89135

For additional information regarding sites for this trial call 919-319-9374, Las Vegas

97239

For additional information regarding sites for this trial call 919-319-9374, Portland

98109

For additional information regarding sites for this trial call 919-319-9374, Seattle

02111

For additional information regarding sites for this trial call 919-319-9374, Boston

Sponsors
All Listed Sponsors
lead

Aptevo Therapeutics

INDUSTRY